Study #2025-0423
Phase 2 study of BTKi-Rituximab induction followed by Glofitamab consolidation in high risk untreated MCL patients - WINDOW-4 study
MD Anderson Study Status
Enrolling
Treatment Agent
Acalabrutinib, Rituximab, Glofitamab
Description
to learn if giving glofitamab after treatment with BTKi-rituximab can help to control high-risk MCL.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Phase 2 Study, MCL, BTKi, Rituximab, Glofitamab
Study phase:
Phase II
Physician name:
Fateeha Furqan
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.